Long-term safety of satralizumab in neuromyelitis optica spectrum disorder: results from the open-label extension periods of SAkuraSky and SAkuraStar

被引：0
|
作者：
Greenberg, B. M. [1 ]
de Seze, J. [2 ]
Saiz, A. [3 ,4 ]
Yamamura, T. [5 ]
Yeaman, M. [6 ]
Marcillat, C. [7 ]
Kou, X. [7 ]
Weber, K. [7 ]
Blondeau, K. [7 ]
Weinshenker, B. G. [8 ]
Patti, F. [9 ,10 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Hop Hautepierre, Strasbourg, France
[3] Hosp Clin Barcelona, Serv Neurol, Barcelona, Spain
[4] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
[5] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo, Japan
[6] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
[8] Mayo Clin, Rochester, MN USA
[9] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Catania, Italy
[10] Multiple Sclerosis Ctr AOU Policlin G Rodolico Sa, Catania, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P023
引用
收藏
页码：147 / 148
页数：2
相关论文
共 50 条
  • [31] Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease
    Barreras, Paula
    Vasileiou, Eleni S.
    Filippatou, Angeliki G.
    Fitzgerald, Kathryn C.
    Levy, Michael
    Pardo, Carlos A.
    Newsome, Scott D.
    Mowry, Ellen M.
    Calabresi, Peter A.
    Sotirchos, Elias S.
    NEUROLOGY, 2022, 99 (22) : E2504 - E2516
  • [32] Efficacy and safety of satralizumab monotherapy for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD): results from SAkuraStar, a double-blind placebo-controlled Phase 3 clinical study
    Traboulsee, A.
    Greenberg, B.
    Bennett, J. L.
    Szczechowski, L.
    Fox, E.
    Shkrobot, S.
    Yamamura, T.
    Terada, Y.
    Kawata, Y.
    Wright, P.
    von Budingen, H. -C.
    Klingelschmitt, G.
    Gianella-Borradori, A.
    Weinshenker, B. G.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 287 - 288
  • [33] Contributors to Long-Term Disability in Patients with Neuromyelitis Optica Spectrum Disorder
    Levy, Michael
    Mealy, Maureen
    Mossburg, Sarah
    Kim, Su-Hyun
    Borisow, Nadja
    Lopez, Reydmar
    Ospina, Juan Pablo
    Scheel, Michael
    Yeshokumar, Anusha
    Palace, Jacqueline
    Andres Jimenez-Arango, Jorge
    Paul, Friedemann
    Kim, Ho Jin
    NEUROLOGY, 2018, 90
  • [34] Long-term outcome of pregnant women with neuromyelitis optica spectrum disorder
    Kim, S. -H.
    Huh, S. -Y.
    Jang, H. -M.
    Park, N. Y.
    Lee, M. Y.
    Hyun, J. -W.
    Kim, H. J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 586 - 587
  • [35] Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial
    Cree, Bruce A. C.
    Kim, Ho Jin
    Weinshenker, Brian G.
    Pittock, Sean J.
    Wingerchuk, Dean M.
    Fujihara, Kazuo
    Paul, Friedemann
    Cutter, Gary R.
    Marignier, Romain
    Green, Ari J.
    Aktas, Orhan
    Hartung, Hans -Peter
    She, Dewei
    Rees, William
    Smith, Michael
    Cimbora, Daniel
    Katz, Eliezer
    Bennett, Jeffrey L.
    LANCET NEUROLOGY, 2024, 23 (06): : 588 - 602
  • [36] Long-term safety of azathioprine for treatment of neuromyelitis optica spectrum disorders
    Galvao Ribeiro Gomes, Ana Beatriz Ayroza
    Pitombeira, Milena Sales
    Sato, Douglas Kazutoshi
    Callegaro, Dagoberto
    Apostolos-Pereira, Samira Luisa
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2021, 79 (03) : 229 - 232
  • [37] Safety of long-term use of linezolid: results of an open-label study
    Vazquez, Jose A.
    Arnold, Anthony C.
    Swanson, Robert N.
    Biswas, Pinaki
    Bassetti, Matteo
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1347 - 1354
  • [38] Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia
    Drulovic, Jelena
    Martinovic, Vanja
    Basuroski, Irena Dujmovic
    Mesaros, Sarlota
    Mader, Simone
    Weinshenker, Brian
    Pekmezovic, Tatjana
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 36
  • [39] Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial
    Grossman, J
    Smith, LJ
    Wilson, AM
    Thyrum, PT
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 82 (04) : 361 - 369
  • [40] LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN SCHIZOPHRENIA: RESULTS OF A 22 MONTH, OPEN-LABEL EXTENSION STUDY
    Pikalov, Andrei
    Correll, Christoph
    Cucchiaro, Josephine
    Silva, Robert
    Hsu, Jay
    Loebel, Antony
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S178 - S178
12345